Bradley J. NBJ: “The US supplement industry is $37 billion, not $12 billion” [Internet]. Nutr Bus J. 2015. Available from: URL: http://www.nutraingredients-usa.com/Markets/NBJ-The-US-supplement-industry-is-37-billion-not-12-billion.
Food and Drug Administration. Dietary Supplement Health and Education Act of 1994. US Dep Heal Hum Serv. 1994; Available from: URL: http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/ucm148003.htm#sec3.
Food and Drug Administration. What is a dietary supplement? [Internet]. 2015. Available from: URL: http://www.fda.gov/AboutFDA/Transparency/Basics/ucm195635.htm.
Geller A, Shehab N, Weidle N, Lovegrove M, Wolpert B, Timbo B, et al. Emergency department visits for adverse events related to dietary supplements. N Engl J Med. 2015;373:1531–40. This reference is of importance due to its novelty and wide approach to the subject of interest. This provides an overview that allows non-experts to begin familiarizing with the subject.
Stohs SJ, Preuss HG, Shara M. The safety of Citrus aurantium (bitter orange) and its primary protoalkaloid p‐synephrine. Phytother Res. 2011;25:1421–8.
Fugh-Berman A. Citrus aurantium, an ingredient of dietary supplements marketed for weight loss: current status of clinical and basic research. Exp Biol Med. 2004;229:698–704.
Allison DB, Cutter G, Poehlman ET, Moore DR, Barnes S. Exactly which synephrine alkaloids does Citrus aurantium (bitter orange) contain? Int J Obes (Lond). 2005;29:443–6.
Haaz S, Fontaine KR, Cutter G, Limdi N, Perumean-Chaney S, Allison DB. Citrus aurantium and synephrine alkaloids in the treatment of overweight and obesity: an update. Obes Rev. 2006;7:79–88.
Colker CM, Kalman DS, Torina GC, Perlis T, Street C. Effects of Citrus aurantium extract, caffeine, and St. John’s Wort on body fat loss, lipid levels, and mood states in overweight healthy adults. Curr Ther Res. 1999;60:145–53.
Kalman DS, Colker CM, Shi QH, Swain MA. Effects of a weight-loss aid in healthy overweight adults: double-blind, placebo-controlled clinical trial. Curr Ther Res Exp. 2000;61:199–205.
Stohs SJ, Preuss HG, Keith SC, Keith PL, Miller H, Kaats GR. Effects of p-synephrine alone and in combination with selected bioflavonoids on resting metabolism, blood pressure, heart rate and self-reported mood changes. Int J Med Sci. 2011;8:295–301.
Kim G-S, Park HJ, Woo J-H, Kim M-K, Koh P-O, Min W, et al. Citrus aurantium flavonoids inhibit adipogenesis through the Akt signaling pathway in 3T3-L1 cells. BMC Complement Altern Med [Internet]. 2012;12:31.
Bent S, Padula A, Neuhaus J. Safety and efficacy of Citrus aurantium for weight loss. Am J Cardiol. 2004;94:1359–61.
Kaats GR, Miller H, Preuss HG, Stohs SJ. A 60day double-blind, placebo-controlled safety study involving Citrus aurantium (bitter orange) extract. Food Chem Toxicol. 2013;55:358–62.
Stohs SJ. Assessment of the adverse event reports associated with Citrus aurantium (bitter orange) from April 2004 to October 2009. J Funct Foods. 2010;2:235–8.
Russell PJ, Swindells C. Chemical characterisation of Hoodia gordonii extract. Food Chem Toxicol. 2012;50(S):6–13.
Van Heerden FR. Hoodia gordonii: a natural appetite suppressant. J Ethnopharmacol. 2008;119:434–7.
Smith C, Krygsman A. Hoodia gordonii: to eat, or not to eat. J Ethnopharmacol. 2014;155:987–91.
MacLean DB, Luo LG. Increased ATP content/production in the hypothalamus may be a signal for energy-sensing of satiety: studies of the anorectic mechanism of a plant steroidal glycoside. Brain Res. 2004;1020:1–11.
Le Nevé B, Foltz M, Daniel H, Gouka R. The steroid glycoside H.g.-12 from Hoodia gordonii activates the human bitter receptor TAS2R14 and induces CCK release from HuTu-80 cells. Am J Physiol Gastrointest Liver Physiol. 2010;299:G1368–75.
Blom WAM, Abrahamse SL, Bradford R, Duchateau GSMJE, Theis W, Orsi A, et al. Effects of 15-d repeated consumption of Hoodia gordonii purified extract on safety, ad libitum energy intake, and body weight in healthy, overweight women: a randomized controlled trial. Am J Clin Nutr. 2011;94:1171–81.
Yamoneka J, Malumba P, Blecker C, Gindo M, Richard G, Fauconnier M-L, et al. Physicochemical properties and thermal behaviour of African wild mango (Irvingia gabonensis) seed fat. LWT - Food Sci Technol. 2015;64:989–96.
Ribeiro SMR, Barbosa LCA, Queiroz JH, Knödler M, Schieber A. Phenolic compounds and antioxidant capacity of Brazilian mango (Mangifera indica L.) varieties. Food Chem. 2008;110:620–6.
Arogba SS. Phenolics, antiradical assay and cytotoxicity of processed mango (Mangifera indica) and bush mango (Irvingia gabonensis) kernels. Niger Food J. 2014;32:62–72.
Oben JE, Ngondi JL, Blum K. Inhibition of Irvingia gabonensis seed extract (OB131) on adipogenesis as mediated via down regulation of the PPARgamma and leptin genes and up-regulation of the adiponectin gene. Lipids Health Dis. 2008;7:44.
Ngondi JL, Oben JE, Minka SR. The effect of Irvingia gabonensis seeds on body weight and blood lipids of obese subjects in Cameroon. Lipids Health Dis. 2005;4:12.
Oben JE, Ngondi JL, Momo CN, Agbor GA, Sobgui CSM. The use of a Cissus quadrangularis/Irvingia gabonensis combination in the management of weight loss: a double-blind placebo-controlled study. Lipids Health Dis. 2008;7:12.
Onakpoya I, Davies L, Posadzki P, Ernst E. The efficacy of Irvingia gabonensis supplementation in the management of overweight and obesity: a systematic review of randomized controlled trials. J Diet Suppl. 2013;10:29–38.
Farah A, Donangelo CM. Phenolic compounds in coffee. Brazilian J Plant Physiol. 2006;18:23–36.
Tsao R. Chemistry and biochemistry of dietary polyphenols. Nutrients. 2010;2:1231–46.
Mullin G. Supplements for weight loss: hype or help for obesity? Part II. The inside scoop on green coffee bean extract. Nutr Clin Pract. 2015;30:311–2. This reference is of importance due to its novelty and wide approach to the subject of interest. This provides an overview that allows non-experts to begin familiarizing with the subject.
Flanagan J, Bily A, Rolland Y, Roller M. Lipolytic activity of Svetol®, a decaffeinated green coffee bean extract. Phytother Res. 2014;28:946–8.
Shimoda H, Seki E, Aitani M. Inhibitory effect of green coffee bean extract on fat accumulation and body weight gain in mice. BMC Complement Altern Med. 2006;6:9.
Cho AS, Jeon SM, Kim MJ, Yeo J, Seo KI, Choi MS, et al. Chlorogenic acid exhibits anti-obesity property and improves lipid metabolism in high-fat diet-induced-obese mice. Food Chem Toxicol. 2010;48:937–43.
Onakpoya I, Terry R, Ernst E. The use of green coffee extract as a weight loss supplement: a systematic review and meta-analysis of randomised clinical trials. Gastroenterol Res Pract. 2011;2011:1–6.
Kavitha C, Rajamani K, Vadivel E. Coleus forskohlii: a comprehensive review on morphology, phytochemistry and pharmacological aspects. J Med Plants Res. 2010;4:278–85.
Insel PA, Ostrom RS. Forskolin as a tool for examining adenylyl cyclase expression, regulation, and G protein signaling. Cell Mol Neurobiol. 2003;23:305–14.
Godard MP, Johnson BA, Richmond SR. Body composition and hormonal adaptations associated with forskolin consumption in overweight and obese men. Obes Res. 2005;13:1335–43.
Henderson S, Magu B, Rasmussen C, Lancaster S, Kerksick C, Smith P, et al. Effects of coleus forskohlii supplementation on body composition and hematological profiles in mildly overweight women. J Int Soc Sports Nutr. 2005;2:54–62.
Peng J, Yuan JP, Wu CF, Wang JH. Fucoxanthin, a marine carotenoid present in brown seaweeds and diatoms: metabolism and bioactivities relevant to human health. Mar Drugs. 2011;9:1806–28.
Hu X, Li Y, Li C, Fu Y, Cai F, Chen Q, et al. Combination of fucoxanthin and conjugated linoleic acid attenuates body weight gain and improves lipid metabolism in high-fat diet-induced obese rats. Arch Biochem Biophys. 2012;519:59–65.
Beppu F, Hosokawa M, Niwano Y, Miyashita K. Effects of dietary fucoxanthin on cholesterol metabolism in diabetic/obese KK-Ay mice. Lipids Health Dis. 2012;11:112.
Wu M, Singh SB, Wang J, Chung CC, Salituro G, Karanam BV, et al. Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes. Proc Natl Acad Sci. 2011;108:5378–83.
Gammone MA, D’Orazio N. Anti-obesity activity of the marine carotenoid fucoxanthin. Mar Drugs. 2015;13:2196–214.
Kang S-I, Ko H-C, Shin H-S, Kim H-M, Hong Y-S, Lee N-H, et al. Fucoxanthin exerts differing effects on 3T3-L1 cells according to differentiation stage and inhibits glucose uptake in mature adipocytes. Biochem Biophys Res Commun. 2011;409:769–74.
D’Orazio N, Gemello E, Gammone MA, De Girolamo M, Ficoneri C, Riccioni G. Fucoxantin: a treasure from the sea. Mar Drugs. 2012;10:604–16.
Maeda H, Hosokawa M, Sashima T, Funayama K, Miyashita K. Fucoxanthin from edible seaweed, Undaria pinnatifida, shows antiobesity effect through UCP1 expression in white adipose tissues. Biochem Biophys Res Commun. 2005;332:392–7.
Buras E. The effects of XanthigenTM supplementation on body composition, serum markers of the metabolic syndrome, and hepaptic enzyme levels in an obese population. Honors Theses. The University of Southern Mississippi; 2012.
Abidov M, Ramazanov Z, Seifulla R, Grachev S. The effects of XanthigenTM in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat. Diabetes Obes Metab. 2010;12:72–81.
Bredsdorff L, Wedebye EB, Nikolov NG, Hallas-Møller T, Pilegaard K. Raspberry ketone in food supplements—high intake, few toxicity data—a cause for safety concern? Regul Toxicol Pharmacol. 2015;73:196–200.
Park KS. Raspberry ketone increases both lipolysis and fatty acid oxidation in 3T3-L1 adipocytes. Planta Med. 2010;76:1654–8.
Park KS. Raspberry ketone, a naturally occurring phenolic compound, inhibits adipogenic and lipogenic gene expression in 3T3-L1 adipocytes. Pharm Biol. 2015;53:870–5. This reference is of importance due to its novelty and wide approach to the subject of interest. This provides an overview that allows non-experts to begin familiarizing with the subject.
Morimoto C, Satoh Y, Hara M, Inoue S, Tsujita T, Okuda H. Anti-obese action of raspberry ketone. Life Sci. 2005;77:194–204.
Alonso-Sande M, Teijeiro-Osorio D, Remuñán-López C, Alonso MJ. Glucomannan, a promising polysaccharide for biopharmaceutical purposes. Eur J Pharm Biopharm. 2009;72:453–62.
Davé V, McCarthy S. Review of konjac glucomannan. J Polym Environ. 1997;5:237–41.
Keithley J, Swanson B. Glucomannan and obesity: a critical review. Altern Ther Health Med. 2005;11:30–4.
Keithley JK, Swanson B, Mikolaitis SL, DeMeo M, Zeller JM, Fogg L, et al. Safety and efficacy of glucomannan for weight loss in overweight and moderately obese adults. J Obes. 2013;2013:610908.
Onakpoya I, Posadzki P, Ernst E. The efficacy of glucomannan supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials. J Am Coll Nutr. 2014;33:70–8.
Sood N, Baker WL, Coleman CI. Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. Am J Clin Nutr. 2008;88:1167–75.
Cloetens L, Ulmius M, Johansson-Persson A, Åkesson B, Önning G. Role of dietary beta-glucans in the prevention of the metabolic syndrome. Nutr Rev. 2012;70:444–58.
El Khoury D, Cuda C, Luhovyy BL, Anderson GH. Beta glucan: health benefits in obesity and metabolic syndrome. J Nutr Metab. 2012;2012:851362.
Synytsya A, Míčková K, Synytsya A, Jablonský I, Spěváček J, Erban V, et al. Glucans from fruit bodies of cultivated mushrooms Pleurotus ostreatus and Pleurotus eryngii: structure and potential prebiotic activity. Carbohydr Polym. 2009;76:548–56.
Maki KC, Galant R, Samuel P, Tesser J, Witchger MS, Ribaya-Mercado JD, et al. Effects of consuming foods containing oat beta-glucan on blood pressure, carbohydrate metabolism and biomarkers of oxidative stress in men and women with elevated blood pressure. Eur J Clin Nutr. 2007;61:786–95.
Queenan KM, Stewart ML, Smith KN, Thomas W, Fulcher RG, Slavin JL. Concentrated oat beta-glucan, a fermentable fiber, lowers serum cholesterol in hypercholesterolemic adults in a randomized controlled trial. Nutr J. 2007;6:6.
Davy BM, Melby CL, Beske SD, Ho RC, Davrath LR, Davy KP. Oat consumption does not affect resting casual and ambulatory 24-h arterial blood pressure in men with high-normal blood pressure to stage I hypertension. J Nutr. 2002;132:394–8.
Kabir M, Oppert J-M, Vidal H, Bruzzo F, Fiquet C, Wursch P, et al. Four-week low-glycemic index breakfast with a modest amount of soluble fibers in type 2 diabetic men. Metabolism. 2002;51:819–26.
Lyly M, Liukkonen KH, Salmenkallio-Marttila M, Karhunen L, Poutanen K, Lähteenmäki L. Fibre in beverages can enhance perceived satiety. Eur J Nutr. 2009;48:251–8.
Lyly M, Ohls N, Lähteenmäki L, Salmenkallio-Marttila M, Liukkonen K-H, Karhunen L, et al. The effect of fibre amount, energy level and viscosity of beverages containing oat fibre supplement on perceived satiety. Food Nutr Res. 2010;54:1–8.
Willis HJ, Eldridge AL, Beiseigel J, Thomas W, Slavin JL. Greater satiety response with resistant starch and corn bran in human subjects. Nutr Res. 2009;29:100–5.
Kim H, Behall KM, Vinyard B, Conway JM. Short-term satiety and glycemic response after consumption of whole grains with various amounts of beta-glucan. Cereal Foods World. 2006;51:29–33.
Peters HPF, Boers HM, Haddeman E, Melnikov SM, Qvyjt F. No effect of added ß-glucan or of fructooligosaccharide on appetite or energy intake. Am J Clin Nutr. 2009;89:58–63.
Mudgil D, Barak S, Khatkar B. Guar gum: processing, properties and food applications: a review. J Food Sci Technol. 2014;51:409–18.
Pasman WJ, Westerterp-Plantenga MS, Muls E, Vansant G, van Ree J, Saris WH. The effectiveness of long-term fibre supplementation on weight maintenance in weight-reduced women. Int J Obes Relat Metab Disord. 1997;21:548–55.
Pittler MH, Ernst E. Guar gum for body weight reduction: meta-analysis of randomized trials. Am J Med. 2001;110:724–30.
Dall’Alba V, Silva FM, Antonio JP, Steemburgo T, Royer CP, Almeida JC, et al. Improvement of the metabolic syndrome profile by soluble fibre—guar gum—in patients with type 2 diabetes: a randomised clinical trial. Br J Nutr. 2013;110:1601–10.
Mattes RD. Effects of a combination fiber system on appetite and energy intake in overweight humans. Physiol Behav. 2007;90:705–11.
Saper RB, Eisenberg DM, Phillips RS. Common dietary supplements for weight loss. Am Fam Physician. 2004;70:1731–8.
Van Bennekum AM, Nguyen DV, Schulthess G, Hauser H, Phillips MC. Mechanisms of cholesterol-lowering effects of dietary insoluble fibres: relationships with intestinal and hepatic cholesterol parameters. Br J Nutr. 2005;94:331–7.
Ernst E, Pittler MH. Chitosan as a treatment for body weight reduction? A meta-analysis. Perfusion. 1998;11:461–5.
Pereira A, Guedes AD, Verreschi ITN, Santos RD, Martinez TLR. Obesity and its association with other cardiovascular risk factors in school children in Itapetininga. Brazil Arq Bras Cardiol. 2009;93:253–60.
Schiller RN, Barrager E, Schauss AG, Nichols EJ. A randomized, double-blind, placebo-controlled study examining the effects of a rapidly soluble chitosan dietary supplement on weight loss and body composition in overweight and mildly obese individuals. JANA. 2001;4:42–9.
Mhurchu CN, Poppitt SD, McGill A-T, Leahy FE, Bennett DA, Lin RB, et al. The effect of the dietary supplement, Chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults. Int J Obes Relat Metab Disord. 2004;28:1149–56.
Guerciolini R, Radu-Radulescu L, Boldrin M, Dallas J, Moore R. Comparative evaluation of fecal fat excretion induced by orlistat and chitosan. Obes Res. 2001;9:364–7.
Vinson J, Kharrat HA, Shuta D. Investigation of an amylase inhibitor on human glucose absorption after starch consumption. Open Nutraceuticals J. 2009;2009:88–91.
Celleno L, Tolaini MV, D’Amore A, Perricone NV, Preuss HG. A Dietary supplement containing standardized Phaseolus vulgaris extract influences body composition of overweight men and women. Int J Med Sci. 2007;4:45–52.
Onakpoya I, Aldaas S, Terry R, Ernst E. The efficacy of Phaseolus vulgaris as a weight-loss supplement: a systematic review and meta-analysis of randomised clinical trials. Br J Nutr. 2011;106:196–202.
Heymsfield SB, Allison DB, Vasselli JR, Pietrobelli A, Greenfield D, Nunez C. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. JAMA. 1998;280:1596–600.
Astell KJ, Mathai ML, Su XQ. Plant extracts with appetite suppressing properties for body weight control: a systematic review of double blind randomized controlled clinical trials. Complement Ther Med. 2013;21:407–16.
De Lira-Garcia C, Souto-Gallardo M, Bacardi-Gascon M, Jimenez-Cruz A. A systematic review of the effectiveness of alternative weight-loss products’ ingredients. Rev Salud Publica (Bogota). 2008;10:818–30.
Kim K-Y, Lee HN, Kim YJ, Park T. Garcinia cambogia extract ameliorates visceral adiposity in C57BL/6J mice fed on a high-fat diet. Biosci Biotechnol Biochem. 2008;72:1772–80.
Kim YJ, Choi MS, Park YB, Kim SR, Lee MK, Jung UJ. Garcinia cambogia attenuates diet-induced adiposity but exacerbates hepatic collagen accumulation and inflammation. World J Gastroenterol. 2013;19:4689–701.
Lobb A. Hepatoxicity associated with weight-loss supplements: a case for better post-marketing surveillance. World J Gastroenterol. 2009;15:1786–7.
Márquez F, Babio N, Bulló M, Salas-Salvadó J. Evaluation of the safety and efficacy of hydroxycitric acid or Garcinia cambogia extracts in humans. Crit Rev Food Sci Nutr. 2012;52:585–94.
Semwal RB, Semwal DK, Vermaak I, Viljoen A. A comprehensive scientific overview of Garcinia cambogia. Fitoterapia. 2015;102:134–48.
Pittler M, Ernst E. Dietary supplements for body-weight reduction: a systematic review. Am J Clin Nutr. 2004;79:529–36.